Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (OTCPK:TSOI)

Fundamentals Snapshot (OTCPK:TSOI)

Current News (OTCPK:TSOI)

Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells

Business Wire 13 days ago

Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell(TM) Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial

Business Wire July 18, 2022

John Hopkin's University Publishes Efficacy of QuadraMune(TM) Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

Business Wire May 27, 2022

Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board

Business Wire May 25, 2022

Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial

Business Wire May 23, 2022

Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell(TM) for Treatment of COPD

Business Wire May 12, 2022

Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell(TM) Universal Donor Adult Stem Cells

Business Wire May 9, 2022

Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell(TM) Universal Donor Stem Cell Drug

Business Wire May 2, 2022

Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell(TM) to Stimulate Healing of Injured Lung Tissue

Business Wire April 19, 2022

Opinion & Analysis (OTCPK:TSOI)

No current opinion is available.

Bullboard Posts (OTCPK:TSOI)

Huge news!

Wow these guys never fail to impress. Todays news is further proof that these cellular medicines will be here to stay. From treating...
jefftrade11 - January 25, 2021

Interesting market here

I suppose I’ll go ahead and kick this board off. I’ve been taking neuenergy for the caffeine and pt since a hospitalization 3 years ago...
JuiceNewton - October 16, 2018